Shuaibu Aliyu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shuaibu Aliyu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Abdulnasir Salihu
1 shared publication- Dalhatu Muhammad Ahmad
Department of Clinical Pharmacy and Pharmacy Practice, Ahmadu Bello University
1 shared publication Don Eliseo Lucero-Prisno
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK
1 shared publicationHaruna Rashid Muhammad
Department of Pharmacy, EHA Clinic, Kano, Nigeria
1 shared publicationIbrahim Abdu-Aguye
1 shared publication- Jamilu Ya'U
Department of Pharmacology and Toxicology, Usmanu Danfodiyo University, Sokoto, Nigeria
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by SAGE Publications in Journal of Multimorbidity and Comorbidity
- Vol. 14
Comparison of the quality of life of comorbid and non-comorbid people living with HIV/AIDS in a Nigerian secondary healthcare facility
Introduction: Quality of life (QoL) is a vital healthcare indicator among people living with human immunodeficiency virus (PLWHA). Assessing the effects of comorbidities on QoL among PLWHA is of clinical and public health importance. This study compared the QoL of comorbid and non-comorbid PLWHA at St. Gerard’s Catholic Hospital (SGCH), Kaduna. Methods: This was a prospective cross-sectional study of 178 conveniently selected and stratified comorbid PLWHA and 172 non-comorbid PLWHA receiving care at the facility. Data was collected using a structured, interviewer-administered instrument. The QoL scores were statistically compared using the Mann‒Whitney U test. P<0.05 was considered statistically significant for all the analyses. Results: Most respondents were aged 35 – 54 years (65.2% and 66.4% for comorbid and non-comorbid patients respectively), were female (70.8% and 69.2% for comorbid and non-comorbid patients respectively) and married (67.4% and 59.3% for comorbid and non-comorbid patients respectively). For all QoL domains (perception of QoL and general health, physical health, psychological health, level of independence, social relationship, environment, and spirituality/religion/personal beliefs), there was evidence the distribution of values was significantly lower in the comorbid PLWHA compared to the non-comorbid PLWHA (p<0.001), with the largest difference seen for physical health. The mean physical health (interquartile range) was 9 (7-10) and 17 (15-19) for comorbid and non-comorbid PLWHA respectively. The most prevalent comorbidities among the PLWHA were hypertension 97 (54.49%) and diabetes 36 (20.22%). Conclusion: Non-comorbid PLWHA had better QoL than comorbid PLWHA in all the QoL domains and the greatest difference was observed in physical health. Special efforts should be made to improve the QoL of comorbid PLWHA.
- 1 January 2024
- Published by SAGE Publications in Journal of Multimorbidity and Comorbidity
- Vol. 14
Open AccessComparison of the quality of life of comorbid and non-comorbid people living with HIV/AIDS in a Nigerian secondary healthcare facility
Introduction: Quality of life (QoL) is a vital healthcare indicator among people living with human immunodeficiency virus (PLWHA). Assessing the effects of comorbidities on QoL among PLWHA is of clinical and public health importance. This study compared the QoL of comorbid and non-comorbid PLWHA at St. Gerard’s Catholic Hospital (SGCH), Kaduna. Methods: This was a prospective cross-sectional study of 178 conveniently selected and stratified comorbid PLWHA and 172 non-comorbid PLWHA receiving care at the facility. Data was collected using a structured, interviewer-administered instrument. The QoL scores were statistically compared using the Mann‒Whitney U test. P<0.05 was considered statistically significant for all the analyses. Results: Most respondents were aged 35 – 54 years (65.2% and 66.4% for comorbid and non-comorbid patients respectively), were female (70.8% and 69.2% for comorbid and non-comorbid patients respectively) and married (67.4% and 59.3% for comorbid and non-comorbid patients respectively). For all QoL domains (perception of QoL and general health, physical health, psychological health, level of independence, social relationship, environment, and spirituality/religion/personal beliefs), there was evidence the distribution of values was significantly lower in the comorbid PLWHA compared to the non-comorbid PLWHA (p<0.001), with the largest difference seen for physical health. The mean physical health (interquartile range) was 9 (7-10) and 17 (15-19) for comorbid and non-comorbid PLWHA respectively. The most prevalent comorbidities among the PLWHA were hypertension 97 (54.49%) and diabetes 36 (20.22%). Conclusion: Non-comorbid PLWHA had better QoL than comorbid PLWHA in all the QoL domains and the greatest difference was observed in physical health. Special efforts should be made to improve the QoL of comorbid PLWHA.
- 4 January 2022
- Published by Neuroscience Society of Nigeria in NIgerian Journal of Neuroscience
- Vol. 13 (4) , 111-118
Comparative Antiseizure Activities of Some Branded and Generic Antiepileptic Drugs in a Nigerian City
Branded antiepileptic drugs (AEDs) are expensive, and in developing countries, cheaper generic equivalents may be used interchangeably. Therefore, this study aimed to compare the antiseizure activities of some available branded and generic AEDs in mice. The physicochemical properties of four generic and branded AEDs (carbamazepine, CAB; sodium valproate, SVP; phenytoin, PHY, and phenobarbitone, PHB) were determined according to pharmacopoeial methods. The organoleptic proper-ties, tablet hardness and thickness of the samples were also assessed. The anticonvulsant effect of AEDs was determined using maximal electroshock (MES) and pentylenetetrazole (PTZ) induced seizure. The samples of AEDs showed uniformly comparable organoleptic properties. The active moiety content for all the samples fell within the acceptable ranges stipulated in the official compendia. A significant statistical difference (p≤0.05) in disintegration time existed between two generic formulations of PHB, PHB01 (4.62±1.17 min), and PHB02 (1.40±0.26 min). Similarly, a significant statistical difference (p≤0.05) in hardness (10.40±0.15 kgF vs 5.61±0.03 kgF) and disintegration time (4.65±0.49 min vs 0.64±0.30 min) was observed between the two brands of CAB (CAB02 and CAB03 respectively). No significant statistical difference exists in mean recovery time between control (5.70±0.72 min) and treatment groups (CAB01, 6.50±0.65 min) in the MEST. In the PTZ test, there was a significant (p≤0.001) difference in the mean onset of clonic spasm between control (10.03±0.75 min) and PHB, PHB01 (17.50±0.99 min) 30 min post-treatment. In conclusion, no significant variation in the physicochemical and antiseizure activity of branded and generic formulations of AEDs was observed
- 4 January 2022
- Published by Neuroscience Society of Nigeria in NIgerian Journal of Neuroscience
- Vol. 13 (4) , 111-118
Comparative Antiseizure Activities of Some Branded and Generic Antiepileptic Drugs in a Nigerian City
Branded antiepileptic drugs (AEDs) are expensive, and in developing countries, cheaper generic equivalents may be used interchangeably. Therefore, this study aimed to compare the antiseizure activities of some available branded and generic AEDs in mice. The physicochemical properties of four generic and branded AEDs (carbamazepine, CAB; sodium valproate, SVP; phenytoin, PHY, and phenobarbitone, PHB) were determined according to pharmacopoeial methods. The organoleptic proper-ties, tablet hardness and thickness of the samples were also assessed. The anticonvulsant effect of AEDs was determined using maximal electroshock (MES) and pentylenetetrazole (PTZ) induced seizure. The samples of AEDs showed uniformly comparable organoleptic properties. The active moiety content for all the samples fell within the acceptable ranges stipulated in the official compendia. A significant statistical difference (p≤0.05) in disintegration time existed between two generic formulations of PHB, PHB01 (4.62±1.17 min), and PHB02 (1.40±0.26 min). Similarly, a significant statistical difference (p≤0.05) in hardness (10.40±0.15 kgF vs 5.61±0.03 kgF) and disintegration time (4.65±0.49 min vs 0.64±0.30 min) was observed between the two brands of CAB (CAB02 and CAB03 respectively). No significant statistical difference exists in mean recovery time between control (5.70±0.72 min) and treatment groups (CAB01, 6.50±0.65 min) in the MEST. In the PTZ test, there was a significant (p≤0.001) difference in the mean onset of clonic spasm between control (10.03±0.75 min) and PHB, PHB01 (17.50±0.99 min) 30 min post-treatment. In conclusion, no significant variation in the physicochemical and antiseizure activity of branded and generic formulations of AEDs was observed